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Abstract
 
Current strategies for the immunotherapy of melanoma include augmentation of the immune
response to tumor antigens represented by melanosomal proteins such as tyrosinase, gp100, and
MART-1. The possibility that intentional targeting of tumor antigens representing normal
proteins can result in autoimmune toxicity has been postulated but never demonstrated previ-
ously in humans. In this study, we describe a patient with metastatic melanoma who developed
inflammatory lesions circumscribing pigmented areas of skin after an infusion of MART-1–
 
specific CD8
 
1
 
 T cell clones. Analysis of the infiltrating lymphocytes in skin and tumor biopsies
using T cell–specific peptide–major histocompatibility complex tetramers demonstrated a local-
 
ized predominance of MART-1–specific CD8
 
1
 
 T cells (
 
.
 
28% of all CD8 T cells) that was
identical to the infused clones (as confirmed by sequencing of the complementarity-determin-
ing region 3). In contrast to skin biopsies obtained from the patient before T cell infusion,
postinfusion biopsies demonstrated loss of MART-1 expression, evidence of melanocyte dam-
age, and the complete absence of melanocytes in affected regions of the skin. This study pro-
vides, for the first time, direct evidence in humans that antigen-specific immunotherapy can
target not only antigen-positive tumor cells in vivo but also normal tissues expressing the
shared tumor antigen.
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Introduction
 
The appearance of vitiligo in melanoma patients is thought
to be the result of immune-mediated destruction of mela-
nocytes through recognition of shared target antigens and
has been associated with clinical response (1, 2). However,
there has been no direct evidence that either a cell-medi-
ated or humoral event is responsible for melanocyte de-
struction, and no demonstration that targeting a specific an-
tigen in melanoma patients results in vitiligo.
Current trials of immunotherapy in melanoma have
been directed at melanocytic differentiation antigens such
as MART-1/MelanA, gp100, and tyrosinase (3–6). To
evaluate the efficacy and potential toxicity of targeting the
MART-1 antigen (7), a clinical trial using adoptively trans-
ferred CD8
 
1
 
 CTL clones was initiated. In this report, we
describe a patient who developed unusual inflammatory
skin lesions after an infusion of MART-1–specific CTLs
and provide direct evidence in humans that antigen-spe-
cific immunotherapy can target not only antigen-positive
tumor cells in vivo but also normal melanocytes expressing
a tumor-associated self-protein.
 
Materials and Methods
 
Generation of MART-1–specific CTL Clones from Peripheral
Blood.
 
Studies using human subjects received prior approval by
the Institutional Review Board at the Fred Hutchinson Cancer
Research Center and the University of Washington. PBMCs
were obtained from donors by leukapheresis. MART-1–specific
CTL clones were generated as described previously (8, 9). In
brief, autologous PBMCs were stimulated using antigen-present-
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ing cells pulsed with the A2-restricted peptide epitope of
MART-1 (M27:AAGIGILTV [10]). After three cycles of stimu-
lation, T cells were cloned by limiting dilution and expanded for
in vitro testing. CTL clones demonstrating specific lysis of M27
peptide–pulsed and MART-1–positive tumor targets in a chro-
mium release assay were selected for infusion. Clones used for in-
fusions 1 and 2 were transduced with the inducible suicide gene,
hygromycin-thymidine kinase (HyTK; a gift of Targeted Genet-
ics Corporation, Seattle, WA, and the National Gene Vector Lab,
Indianapolis, IN; reference 11). CTLs transduced with HyTK ex-
press the resistance marker, hygromycin phosphotransferase, to
permit in vitro selection, and the HSV thymidine kinase gene to
permit in vivo ablation with low dose ganciclovir should toxicity
due to the infused T cells occur. The transduction protocol for
CD8
 
1
 
 CTL clones and characterization of HyTK-transduced T
cells have been described previously (12).
 
Construction of Peptide–MHC Tetramers.
 
Tetramers were
made according to the protocol of Altman et al. (13). In brief,
human 
 
b
 
2-microglobulin and the soluble domain of the HLA-
A2 heavy chain (residues 1–276) linked at its COOH terminus to
a BirA substrate peptide (BSP) were expressed in 
 
Escherichia coli
 
and isolated as an insoluble aggregate. The expressed HLA-A2–
BSP and 
 
b
 
2-microglobulin subunits were solubilized and refolded
together in vitro in the presence of peptide. Folded material was
biotinylated by BirA enzyme. HLA-A2–peptide complexes were
purified on gel filtration and ion exchange columns. Tetrameric
complexes of biotinylated HLA-A2–peptide were produced by
mixing purified, biotinylated heterodimer with NeutrAvidin–PE
(Molecular Probes) at a molar ratio of 4:1. Tetramers presenting
immunogenic epitopes of MART-1 (M27:AAGIGILTV), tyros-
inase (T368:YMDGTMSQV), and gp100 (G154:KTWGQY-
WQV) were constructed.
 
Analysis of Antigen-specific T Cell Frequency in the Peripheral Blood
and Tissue Samples Using Peptide–MHC Tetramers.
 
To evaluate
in vivo persistence of T cells in the peripheral blood, PBMCs
were prepared from samples drawn on day 0 (preinfusion), 1, 7,
and 14 after each infusion and cryopreserved so all samples could
be analyzed simultaneously. At the completion of the study, these
samples were thawed, stained with PE-conjugated M27 peptide–
MHC tetramer (M27-tetramer PE; 50 
 
m
 
g/ml), anti-CD8–FITC
(1:60), and a cocktail of Cy5-PE–conjugated antibodies (anti-
CD4, -CD16, and -CD19) for 40 min at 22
 
8
 
C. Analysis was car-
ried out on the CD8
 
1 
 
Cy5-PE–conjugated lymphocyte subset
to eliminate nonspecific tetramer staining. The frequency of
MART-1–specific CTLs is presented as a fraction of tetramer-
positive, CD8
 
1
 
 lymphocytes over the total number of CD8
 
1
 
cells. This method detects with high specificity a frequency of an-
tigen-specific T cells population as low as 1/10,000 CD8
 
1
 
 cells
or 1/100,000 PBMCs (14–16).
Analysis of T cell infiltrates from tissue samples (skin and tu-
mor) using peptide–MHC tetramers was performed as described
above except that single cell suspensions were prepared from
fresh biopsy samples by mechanical disruption followed by Ficoll
gradient separation before staining.
 
Immunohistochemical Analysis of Antigen Expression in Skin and
Tumor Biopsies.
 
Staining for gp100 (1:100; Dako), MART-1 (1:5;
Novocastra Laboratories, Ltd.), and tyrosinase (1:30; Novocas-
tra Laboratories, Ltd.) was performed by a peroxidase-labeled
streptavidin–biotin method on an automated stainer (Ventana
Medical Systems). Paraffin tissue sections were mounted on ami-
noalkylsilane-treated glass slides and heat treated to optimize anti-
gen retrieval. Endogenous peroxidase activity was blocked by in-
cubation in hydrogen peroxide/methanol. Immunohistochemical
 
staining involved the sequential application of diluted primary
antibody, biotinylated goat secondary antibodies, and then perox-
idase-labeled streptavidin. The antigens were visualized by incu-
bation with aminoethylcarbazole substrate in the presence of hy-
drogen peroxide. Nonimmune mouse IgG in place of specific
antibody was used for negative control sections.
 
Results
 
Clinical Course and Appearance of Inflammatory Skin Lesions
after Adoptive Transfer of MART-1–specific CTLs.
 
The pa-
tient described in this study was a 46-yr-old woman diag-
nosed with metastatic melanoma of unknown primary who
presented with supraclavicular and axillary lymphadenopa-
thy. There was no prior history of vitiligo or ocular symp-
toms. She was initially treated with a chemoimmunother-
apy regimen of carmustine (BCNU), dacarbazine (DTIC),
cisplatin, IFN-
 
a
 
, and high dose IL-2 (17). She received
four cycles of chemoimmunotherapy with a partial re-
sponse but, 3 mo after her last cycle, developed progressive
chest wall and nodal disease. Treatment with adoptively
transferred MART-1–specific CTL clones was initiated at
that time. A total of five T cell infusions consisting of au-
Figure 1. Clinical appearance of inflammatory skin lesions after infu-
sion of autologous MART-1–specific CD81 CTL clones and 500,000
U/m2/d of IL-2. (A) Close-up of well-circumscribed erythematous pap-
ules surrounding pigmented lentiges and nevi on right anterior shoulder.
(B) Close-up of vitiliginous bullae appearing in the previous site of raised
pigmented nevus on the back. 
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tologous MART-1–specific CD8
 
1
 
 CTL clones were ad-
ministered over a 4-mo period. The initial two infusions
were carried out using HyTK-transduced CTL clones at
cell doses of 1.0 and 3.3 
 
3
 
 10
 
9
 
 cells/m
 
2
 
 1 wk apart, fol-
lowed by a 3-wk period of observation for toxicity. No
toxicity was observed and the patient received infusions 3,
4, and 5 consisting of unmodified CTL clones at cell doses
of 3.3 
 
3
 
 10
 
9
 
 cells/m
 
2
 
 3 wk apart, each accompanied by a
14-d course of subcutaneous IL-2 (500,000, 1,000,000, and
2,000,000 U/m
 
2
 
 daily, respectively).
5 d after infusion 3, given with low dose subcutaneous
IL-2 (500,000 U/m
 
2
 
), well-demarcated erythematous pap-
ules appeared around pigmented areas of skin in a targetoid
pattern (Fig. 1). Some lesions developed into bullae and
underwent a vitiliginous change, whereas others began to
spread and coalesce over the next 3 d to cover most of her
back and upper arms (Fig. 2). These lesions were associated
with pruritis and a low-grade fever (37.8
 
8
 
C). Because of
concern that choroidal melanocytes might be involved, the
patient underwent a complete ophthalmologic evaluation.
Visual acuity and field of vision were normal. Fundoscopic
examination revealed a mild anterior uveitis but no evi-
dence of choroiditis or retinitis. 10 d after the infusion, the
infiltrates resolved without intervention. Except for a few
depigmented bullae, the patient retained most of her skin
pigmentation even in areas of previous inflammation. The
IL-2 injections continued to day 14. The patient subse-
quently received infusions 4 and 5 of MART-1–specific T
cells and IL-2 without incident.
During the 4-mo period of T cell infusions, clinical and
radiographic examination demonstrated stabilization of the
tumor masses. 3 mo after the last T cell infusion, the patient
developed central nervous system metastases and a rapidly
enlarging chest wall mass; she received palliative radiother-
apy but expired 6 wk later.
 
Histological and Immunohistochemical Analysis of Inflamma-
tory Skin Infiltrates after Adoptive Transfer of MART-1–specific
T Cells and IL-2 (Infusion 3).
 
On day 6 after infusion 3, a
skin biopsy was obtained over an inflamed site. Histologi-
cally, the skin displayed an intense inflammatory infiltrate
Figure 2. Progression of inflammatory le-
sions appearing around pigmented areas of
skin from days 5–7 after T cell infusion 3. 
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composed of lymphocytes centered around the dermal–
epidermal junction (Fig. 3). Few definite nevus cells could
be identified within the degenerating keratinocytes and the
changes were consistent with a regressing melanocytic ne-
vus replaced by an intense lymphocytic infiltrate. Further
analysis of the lymphocytic infiltrate using horseradish per-
oxidase–conjugated anti-CD3, -CD4, and -CD8 antibod-
ies demonstrated a predominance of CD3
 
1
 
CD4
 
2
 
CD8
 
1
 
lymphocytes.
 
Characterization of Lymphocytes Recovered from the Inflam-
matory Skin Lesion.
 
To further characterize the CD8
 
1
 
 in-
filtrate seen in the skin biopsy at day 6 after infusion 3, a
portion of the biopsy specimen was processed into a single
cell suspension. Staining of these cells using peptide–MHC
 
tetramers revealed a substantial proportion (28.2%) of
CD8
 
1
 
 T cells binding specifically to the M27 peptide–
MHC tetramer (Fig. 4). Staining of CD8
 
1
 
 T cells with
control tetramers (the tyrosinase T368 and gp100 G154
peptide tetramers) was negative. Simultaneous analysis of
the peripheral blood (see below) yielded a frequency of
MART-1–specific CTLs (1.2% of all CD8
 
1
 
 cells) that was
higher than a preinfusion sample (
 
,
 
0.01%) but significantly
lower than that of the skin biopsy sample (28.2%), demon-
strating in vivo persistence of infused MART-1–specific
CTLs in the peripheral blood and preferential localization
to areas of inflammation.
 
Characterization of Lymphocytes Recovered from Tumor
Site.
 
The patient presented with a supraclavicular mass
extending to her right axilla and breast measuring 12 
 
3
 
 17
cm. For a period of 24–48 h after each T cell infusion, the
patient noted tenderness and erythema localized to the
chest wall tumor. To evaluate if transferred T cells infil-
trated the tumor site, core biopsies of the tumor mass were
obtained and divided for histologic analysis and for pro-
cessing into a single cell suspension. Histologically, lym-
phocytic infiltration of the tumor mass was present with
evidence of extensive necrosis. Approximately 38% of
CD8
 
1
 
 lymphocytes from this specimen stained with the
MART-1 (M27) peptide–MHC tetramer but not with
control tetramers (tyrosinase and gp100), demonstrating
that infused MART-1–specific T cells localized not only
to normal melanocytes in the skin but also to tumor sites
(Fig. 4).
Figure 3. Immunohistochemical staining of inflammatory lesion from
skin biopsy obtained on day 6. Hematoxylin and eosin stain demonstrates
intense lymphocytic infiltrate in the dermal–epidermal junction in the
area of melanocytic nevus. Immunohistochemical staining of the same
section demonstrates a predominant population of CD42CD81 lympho-
cytes in infiltrate.
Figure 4. Characterization of lymphocytes harvested from skin biopsy
obtained day 6 after CTL infusion 3 (left) and from tumor biopsy (right).
Same skin sample as in Fig. 3. Flow cytometry analysis (left) using PE-
conjugated M27 tetramer or an irrelevant (T369) tetramer and anti-
CD8–FITC antibody demonstrates a population of MART-1–specific
CTL clones representing .28% of the CD81 lymphocyte population re-
covered from the skin biopsy. Flow cytometry analysis (right) of tumor
biopsy demonstrates MART-1–specific CTL staining comprising .37%
of CD81 lymphocytes in tumor sample. 
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In Vivo Persistence of Infused MART-1–specific CTLs.
 
The preinfusion (day 0) frequency of MART-1–specific T
cells in the peripheral blood of patient 1017-3 was 
 
,
 
1/
10,000. After infusion 1, MART-1–specific T cells ap-
peared in the peripheral blood at a frequency of 1/99
(1.0%) of CD8
 
1
 
 T cells on day 1, but declined rapidly,
dropping by day 14 to a frequency one log lower (1/
1,232). After T cell infusion 3 and IL-2 (500,000 U/m
 
2
 
/d
for 14 d), MART-1–specific T cells maintained a high fre-
quency in vivo (day 1, 1/125; day 7, 1/84; day 14, 1/118)
which included the period when the inflammatory skin re-
action was observed (days 6–10).
Figure 5. Preinfusion and postinfu-
sion skin biopsies stained with hema-
toxylin and eosin (H&E) (top) or anti–
MART-1 horseradish peroxidase
antibody (bottom). In the preinfusion
sample, melanized keratinocytes and
melanocytes are present in the dermal–
epidermal layer. Abundant expression
of MART-1 antigen is seen in basal
melanocytes. In the postinfusion sam-
ple, melanocytes are absent, but resid-
ual melanin is observed coating me-
lanophages (black arrowheads) and
within melanophages (white arrow-
heads). No MART-1 staining is seen. 
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Expression of MART-1 in Tumor and Skin.
 
To deter-
mine if T cell localization to tumor sites and skin was asso-
ciated with expression of MART-1, immunohistochemis-
try was performed on tumor and skin samples.
Analysis of a core biopsy of the chest wall tumor ob-
tained preinfusion demonstrated abundant expression of
MART-1 by 
 
.
 
70% of melanoma cells (data not shown).
Analysis of a preinfusion skin biopsy demonstrated a
layer of melanized keratinocytes underlying pigmented skin
and abundant MART-1 expression among melanocytes
lining the dermal–epidermal junction (Fig. 5; preinfusion).
Examination of a skin biopsy obtained from a previously
inflamed and pigmented site obtained 3 wk after infusion 3
demonstrated no T cell infiltrate and histologic changes
consistent with a regressed nevus: presence of melano-
phages, residual melanin, dermal fibrosis, a lentiginous pat-
tern of keratinocytes, and no melanocytes confirmed by the
complete absence of MART-1 staining (Fig. 5; postinfu-
sion). This finding was confirmed in multiple skin biopsies.
 
Discussion
 
In this study, we describe a patient who developed
unique inflammatory lesions circumscribing pigmented ar-
eas of skin after an infusion of MART-1–specific CD8
 
1
 
 T
cell clones. These lesions resulted in loss of cutaneous me-
lanocytes in involved regions and provide direct evidence
that vitiligo after immunotherapy of melanoma can be at-
tributed to melanocyte-specific CD8
 
1
 
 CTLs. CTL-medi-
ated destruction of melanocytic nevi as a precedent to the
development of vitiligo is consistent with animal models in
which depigmentation occurs after immunization to mu-
rine homologues of human melanoma antigens, tyrosinase-
related protein (TRP)-1 and gp100 (18, 19). However, the
mechanism of vitiligo in humans after immunotherapy has
never been clearly defined. Although antibody- or T cell–
mediated events have been postulated in patients who de-
velop nonmelanoma-associated vitiligo (20, 21), neither T
cells nor antibodies have been identified or recovered from
the site of lesions. This study suggests that one mechanism
by which patients receiving immunotherapy may develop
vitiligo is the induction of CTLs reactive to melanocytic
differentiation antigens such as MART-1. After cognate
antigen recognition, such CTLs may mediate melanocyte
destruction by direct cytotoxicity or initiation of a localized
inflammatory response.
Direct analysis of the T cell population present in inflam-
matory skin lesions and tumor nodule biopsies was per-
formed using peptide–MHC tetramers (22). The inflam-
matory lesions appeared after T cell infusion 3 at a time
when the precursor frequency of MART-1–specific CTLs
in the peripheral blood was 
 
z
 
1% of all CD8
 
1
 
 cells. How-
ever, the infiltrating MART-1–specific T cell population
in the inflamed skin biopsy specimen and a tumor nodule
harvested at this time represented 
 
.
 
28% of CD8
 
1
 
 T cells
in the specimen, demonstrating that transferred CTLs pref-
erentially migrated and localized to antigen-positive tissue.
Histologically, melanocytes in the inflamed tissue were
 
replaced by a T cell infiltrate. Lesions of high antigen den-
sity, e.g., a raised, pigmented mole (Fig. 3), rapidly blis-
tered and developed vitiligo. However, other involved
areas did not undergo depigmentation and subsequent in-
fusions of an equivalent cell dose of MART-1–specific
CTLs with IL-2 (infusions 4 and 5) failed to elicit an in-
flammatory response, even in areas of pigmentation. To
explain this discordance, postinfusion skin biopsies of pre-
viously inflamed sites were taken and analyzed for the pres-
ence of melanocytes and MART-1 expression. Histology
revealed no residual melanocytes, but pigmented kerati-
nocytes and melanophages were seen. Residual melanin
can often appear in these latter cell types after melanocytic
destruction and account for the observed pigmentation.
Immunohistochemical staining for melanosomal proteins
(MART-1, gp100, and tyrosinase) was negative, in contrast
to normal skin where localized staining is observed within
melanocytes. Thus, one explanation is that, during the ini-
tial inflammatory process (after infusion 3), MART-1–spe-
cific CTLs eradicated skin melanocytes but pigmentation
persisted due to residual melanin in keratinocytes and me-
lanophages. In the absence of melanocytes and the MART-1
antigen, no skin toxicity occurred with subsequent infu-
sions of MART-1–specific CTLs and IL-2.
IL-2 therapy alone (without T cells) had been adminis-
tered previously to the patient and was insufficient to in-
duce an autoimmune reaction, suggesting that the coad-
ministration of antigen-specific T cells was essential to the
observed response. The absence of observable toxicity after
infusions of MART-1–specific T cells alone (infusions 1
and 2) suggests that coadministered IL-2 (first given with
infusion 3) may be equally important to the observed T
cell–mediated toxicity. IL-2 may facilitate a breach in toler-
ance by maintaining or expanding the population of infused
MART-1–specific T cells. Analysis of T cell persistence
demonstrated sustained levels of transferred MART-1–spe-
cific CTLs during IL-2 administration of 
 
.
 
1/100, signifi-
cantly higher than that observed after T cell transfer in the
absence of IL-2. Another effect of the administered IL-2
may be increased vascular permeability (23). Although the
dose of IL-2 was only 500,000 U/m
 
2
 
, or at least 20 times
lower than doses typically associated with clinical signs of
vascular leakage, it is possible that even at this low dose, a
subclinical effect on vascular permeability was sufficient to
permit transmigration of circulating MART-1–specific T
cells to the dermal junction where sampling of antigen-
positive melanocytes could occur.
Of note, in our patient and in other patients described
previously as developing vitiligo after melanoma therapy,
the skin toxicity was self-limited and without chronic se-
quelae. Our patient experienced a mild anterior uveitis but
this resolved uneventfully without specific therapy and
there was no evidence of posterior uveitis involving cho-
roidal melanocytes or the pigmented retina. This discor-
dance in toxicity may be due to the locally immunosup-
pressive intraocular microenvironment (24).
Toxicity in this patient was self-limited and restricted to
cutaneous melanocytes. Should this prove to be the only 
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significant adverse effect in subsequent trials, further studies
using larger T cell doses and increased numbers of infusions
in patients with lower tumor burden are warranted.
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